These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 17054057

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF, Blum HE, Geissler M.
    Dtsch Med Wochenschr; 2005 May 27; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
    Rukavitsyn OA, Pop VP.
    Ter Arkh; 2008 May 27; 80(7):80-4. PubMed ID: 18763606
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].
    Campone M, Kerbrat P, Roché H, Bennouna J, Cuillière JC, Le Mevel B, Fumoleau P.
    Bull Cancer; 2003 Oct 27; 90(10):851-64. PubMed ID: 14706914
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225.
    Clin Cancer Res; 2008 May 01; 14(9):2717-25. PubMed ID: 18451237
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Molecularly target therapy].
    Kiyoi H.
    Nihon Rinsho; 2012 Apr 01; 70 Suppl 2():211-6. PubMed ID: 23133955
    [No Abstract] [Full Text] [Related]

  • 14. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Lejeune FJ, Rimoldi D, Speiser D.
    Expert Rev Anticancer Ther; 2007 May 01; 7(5):701-13. PubMed ID: 17492933
    [Abstract] [Full Text] [Related]

  • 15. ENMD-2076 for hematological malignancies.
    How J, Yee K.
    Expert Opin Investig Drugs; 2012 May 01; 21(5):717-32. PubMed ID: 22397360
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Future directions of antibody therapy].
    Oguro M.
    Nihon Rinsho; 2007 Jan 28; 65 Suppl 1():629-36. PubMed ID: 17474471
    [No Abstract] [Full Text] [Related]

  • 18. [Signal transduction by protein tyrosine kinases and antitumor agents].
    Mao YJ, Li HH, Li JF, Shen JS.
    Yao Xue Xue Bao; 2008 Apr 28; 43(4):323-34. PubMed ID: 18664191
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [New therapeutic approaches in glioblastomas].
    Le Guilloux J, Carpentier AF.
    Rev Neurol (Paris); 2008 Apr 28; 164(6-7):554-9. PubMed ID: 18565354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.